Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DYI4L2
|
|||
| Drug Name |
Mecbotamab vedotin
|
|||
| Synonyms |
HTBA3011; HTBA3012
Click to Show/Hide
|
|||
| Drug Type |
Antibody drug conjugate
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 2 | [1] | |
| Soft tissue sarcoma [ICD-11: 2B57; ICD-9: 171] | Phase 2 | [1] | ||
| Company |
BioAtla
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tyrosine-protein kinase UFO (AXL) | Target Info | Inhibitor | [1] |
| NetPath Pathway | FSH Signaling Pathway | |||
| Pathway Interaction Database | Validated transcriptional targets of deltaNp63 isoforms | |||
| Reactome | VEGFA-VEGFR2 Pathway | |||
| WikiPathways | miR-targeted genes in squamous cell - TarBase | |||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of BioAtla | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.